Log in
NASDAQ:IRWD

Ironwood Pharmaceuticals Stock Forecast, Price & News

$11.98
+0.40 (+3.45 %)
(As of 12/4/2020 12:00 AM ET)
Add
Compare
Today's Range
$11.60
Now: $11.98
$12.55
50-Day Range
$9.05
MA: $10.80
$11.99
52-Week Range
$7.99
Now: $11.98
$14.10
Volume4.30 million shs
Average Volume2.02 million shs
Market Capitalization$1.92 billion
P/E Ratio17.36
Dividend YieldN/A
Beta1.46
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the Canada and European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from abdominal pain associated with GI diseases; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, Macau, and Japan, as well as a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Boston, Massachusetts.
Ironwood Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.1Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 3.1 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.62 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:IRWD
CUSIP46333X10
Phone617-621-7722
Employees317

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$428.41 million
Cash Flow$0.60 per share
Book Value$0.04 per share

Profitability

Net Income$21.50 million

Miscellaneous

Market Cap$1.92 billion
Next Earnings Date2/11/2021 (Estimated)
OptionableOptionable
$11.98
+0.40 (+3.45 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IRWD News and Ratings via Email

Sign-up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Ironwood Pharmaceuticals (NASDAQ:IRWD) Frequently Asked Questions

How has Ironwood Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Ironwood Pharmaceuticals' stock was trading at $10.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IRWD stock has increased by 14.1% and is now trading at $11.98.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Ironwood Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Ironwood Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Ironwood Pharmaceuticals?

Wall Street analysts have given Ironwood Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ironwood Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Ironwood Pharmaceuticals' next earnings date?

Ironwood Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for Ironwood Pharmaceuticals
.

How were Ironwood Pharmaceuticals' earnings last quarter?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) issued its quarterly earnings results on Thursday, November, 5th. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.14 by $0.09. The biotechnology company had revenue of $103.50 million for the quarter, compared to analyst estimates of $96.08 million. Ironwood Pharmaceuticals had a net margin of 27.77% and a negative return on equity of 240.80%. Ironwood Pharmaceuticals's revenue for the quarter was down 21.1% on a year-over-year basis. During the same quarter last year, the business posted $0.40 EPS.
View Ironwood Pharmaceuticals' earnings history
.

What guidance has Ironwood Pharmaceuticals issued on next quarter's earnings?

Ironwood Pharmaceuticals issued an update on its FY 2020 After-Hours earnings guidance on Thursday, November, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $370-385 million, compared to the consensus revenue estimate of $369.15 million.

What price target have analysts set for IRWD?

5 brokerages have issued 12-month target prices for Ironwood Pharmaceuticals' shares. Their forecasts range from $9.00 to $14.00. On average, they anticipate Ironwood Pharmaceuticals' stock price to reach $11.60 in the next twelve months. This suggests that the stock has a possible downside of 3.2%.
View analysts' price targets for Ironwood Pharmaceuticals
.

Who are some of Ironwood Pharmaceuticals' key competitors?

What other stocks do shareholders of Ironwood Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), NIC (EGOV), Athabasca Oil Co. (ATH.TO) (ATH), Allergan (AGN), Aegean Marine Petroleum Network (ANW), Micron Technology (MU) and Starbucks (SBUX).

Who are Ironwood Pharmaceuticals' key executives?

Ironwood Pharmaceuticals' management team includes the following people:
  • Mr. Mark Mallon, CEO & Director (Age 57, Pay $2.57M)
  • Mr. Thomas A. McCourt, Pres (Age 63, Pay $974.02k)
  • Ms. Gina R. Consylman C.P.A., CFO, Sr. VP & Treasurer (Age 47, Pay $1.1M)
  • Mr. Brian M. Cali, Co-Founder and Sr. VP of R&D Strategy & External Innovation
  • Mr. G. Todd Milne, Co-Founder and VP of sGC R&D
  • Mr. Jason Rickard, COO & Sr. VP of Operations (Age 49)
  • Ms. Kelly MacDonald, Chief Accounting Officer & VP of Fin.
  • Ms. Meredith Kaya, VP of Investor Relations & Corp. Communications
  • Mr. Conor Kilroy, Sr. VP & Gen. Counsel (Age 38)
  • Mr. Jonathan Rosin, Sr. VP of HR

What is Ironwood Pharmaceuticals' stock symbol?

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

Who are Ironwood Pharmaceuticals' major shareholders?

Ironwood Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.81%), State Street Corp (4.99%), Camber Capital Management LP (4.53%), UBS Asset Management Americas Inc. (2.16%), Charles Schwab Investment Management Inc. (0.71%) and Peregrine Capital Management LLC (0.70%). Company insiders that own Ironwood Pharmaceuticals stock include Gina Consylman, Halley E Gilbert, Julie Mchugh, Kelly Macdonald, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt.
View institutional ownership trends for Ironwood Pharmaceuticals
.

Which major investors are selling Ironwood Pharmaceuticals stock?

IRWD stock was sold by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., BlackRock Inc., State Street Corp, AQR Capital Management LLC, Peregrine Capital Management LLC, Weld Capital Management LLC, Squarepoint Ops LLC, and Federated Hermes Inc.. Company insiders that have sold Ironwood Pharmaceuticals company stock in the last year include Julie Mchugh, Mark G Currie, and Thomas A Mccourt.
View insider buying and selling activity for Ironwood Pharmaceuticals
.

Which major investors are buying Ironwood Pharmaceuticals stock?

IRWD stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Camber Capital Management LP, ExodusPoint Capital Management LP, Acadian Asset Management LLC, Skandinaviska Enskilda Banken AB publ, Jennison Associates LLC, ClariVest Asset Management LLC, and Principal Financial Group Inc..
View insider buying and selling activity for Ironwood Pharmaceuticals
.

How do I buy shares of Ironwood Pharmaceuticals?

Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ironwood Pharmaceuticals' stock price today?

One share of IRWD stock can currently be purchased for approximately $11.98.

How big of a company is Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals has a market capitalization of $1.92 billion and generates $428.41 million in revenue each year. The biotechnology company earns $21.50 million in net income (profit) each year or $0.55 on an earnings per share basis. Ironwood Pharmaceuticals employs 317 workers across the globe.

What is Ironwood Pharmaceuticals' official website?

The official website for Ironwood Pharmaceuticals is www.ironwoodpharma.com.

How can I contact Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals' mailing address is 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]

This page was last updated on 12/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.